Kura Oncology Inc. (KURA) just scored what every biotech dreams of: full FDA approval for its first drug. On Thursday, the agency greenlit Komzifti (ziftomenib), a once-daily pill for patients with relapsed or refractory acute myeloid leukemia that carries a specific genetic mutation called NPM1.

Here's why this matters. AML is an aggressive blood cancer, and when it comes back after initial treatment or doesn't respond in the first place, options get limited quickly. Komzifti targets a subset of these patients whose cancer has what's called an NPM1 mutation. It's the first menin inhibitor to reach the market, which is a fancy way of saying it works through a novel mechanism that blocks a protein interaction driving cancer growth.

The approval rests on data from the KOMET-001 trial. In that study, 21.4% of patients achieved either complete remission or complete remission with partial blood count recovery. That might not sound like a home run percentage, but remember we're talking about people whose cancer has already fought off other treatments. The median time to response was 2.7 months, and 88% of patients who responded did so within six months of starting treatment. For those who achieved remission, it lasted a median of 5.0 months.

Kura isn't going it alone here. The company partnered with Kyowa Kirin back in November 2024 for a global collaboration to develop and sell Komzifti. That deal has already generated $30 million in milestone payments, triggered when the first patient was dosed in KOMET-017, a Phase 3 study testing the drug in a broader AML population.

The financial runway looks solid. Kura ended its September quarter with $609.7 million in pro forma cash. Combined with expected collaboration payments from Kyowa Kirin, management believes they have enough resources to fund the AML program through topline results from KOMET-017.

Wall Street is paying attention. Wedbush maintains an Outperform rating on Kura and just bumped its price target from $36 to $38. Investors are clearly optimistic too. The stock jumped more than 15% to $12.29 on Friday following the approval news.

For a company that's been working toward this moment for years, Thursday's FDA decision represents both validation and a launchpad. The real test now shifts from clinical trials to commercialization—proving that doctors will prescribe Komzifti and that it can carve out meaningful market share in a competitive oncology landscape.